Woodline Partners LP Lowers Holdings in Janux Therapeutics, Inc. $JANX

Key Points

• Woodline Partners LP has decreased its stake in Janux Therapeutics, Inc. by 21.3% in the 1st quarter, selling 395,092 shares and now owning approximately 2.46% of the company worth $39,342,000.
• Analysts have set a positive outlook for Janux Therapeutics, with an average rating of "Buy" and an average target price of $85.55.
• Janux Therapeutics reported a loss of ($0.55) per share in its latest earnings results, which was below analysts' expectations of ($0.48) per share.

Woodline Partners LP lowered its stake in Janux Therapeutics, Inc. (NASDAQ:JANX - Free Report) by 21.3% during the 1st quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 1,457,095 shares of the company's stock after selling 395,092 shares during the period. Woodline Partners LP owned 2.46% of Janux Therapeutics worth $39,342,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds and other institutional investors also recently made changes to their positions in JANX. GAMMA Investing LLC grew its stake in shares of Janux Therapeutics by 1,574.0% in the 1st quarter. GAMMA Investing LLC now owns 1,674 shares of the company's stock worth $45,000 after buying an additional 1,574 shares during the last quarter. US Bancorp DE lifted its position in Janux Therapeutics by 2,402.9% in the 1st quarter. US Bancorp DE now owns 1,727 shares of the company's stock valued at $47,000 after acquiring an additional 1,658 shares in the last quarter. GF Fund Management CO. LTD. bought a new position in Janux Therapeutics in the 4th quarter valued at approximately $59,000. FNY Investment Advisers LLC lifted its position in Janux Therapeutics by 6,928.6% in the 1st quarter. FNY Investment Advisers LLC now owns 2,460 shares of the company's stock valued at $66,000 after acquiring an additional 2,425 shares in the last quarter. Finally, KBC Group NV bought a new position in Janux Therapeutics in the 1st quarter valued at approximately $66,000. Hedge funds and other institutional investors own 75.39% of the company's stock.

Janux Therapeutics Stock Performance

Shares of NASDAQ JANX traded down $0.52 during midday trading on Monday, hitting $23.53. 195,097 shares of the stock traded hands, compared to its average volume of 908,973. The firm has a market capitalization of $1.41 billion, a P/E ratio of -13.09 and a beta of 2.84. Janux Therapeutics, Inc. has a one year low of $21.97 and a one year high of $71.71. The firm has a 50-day moving average of $24.58 and a two-hundred day moving average of $26.30.

Janux Therapeutics (NASDAQ:JANX - Get Free Report) last posted its quarterly earnings data on Thursday, August 7th. The company reported ($0.55) EPS for the quarter, missing the consensus estimate of ($0.48) by ($0.07). Equities analysts forecast that Janux Therapeutics, Inc. will post -1.38 earnings per share for the current fiscal year.

Analyst Ratings Changes

JANX has been the topic of several analyst reports. Truist Financial initiated coverage on Janux Therapeutics in a research report on Wednesday, September 10th. They issued a "buy" rating and a $100.00 price objective on the stock. Guggenheim initiated coverage on Janux Therapeutics in a research report on Wednesday, September 3rd. They issued a "buy" rating and a $72.00 price objective on the stock. Raymond James Financial initiated coverage on Janux Therapeutics in a research report on Friday, July 11th. They issued an "outperform" rating and a $65.00 price objective on the stock. Piper Sandler assumed coverage on Janux Therapeutics in a research report on Monday, August 18th. They issued an "overweight" rating and a $42.00 price objective on the stock. Finally, Stifel Nicolaus reissued a "buy" rating and set a $45.00 price target on shares of Janux Therapeutics in a report on Wednesday, September 10th. Two equities research analysts have rated the stock with a Strong Buy rating, twelve have issued a Buy rating and one has given a Hold rating to the company's stock. According to MarketBeat.com, Janux Therapeutics presently has an average rating of "Buy" and an average price target of $80.92.

Janux Therapeutics Company Profile

Janux Therapeutics, Inc, a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr) platforms technology to treat patients suffering from cancer. The company's clinical candidates comprise JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor or EGFR-TRACTr that is in Phase 1 clinical trial for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma.